| Name | Title | Contact Details |
|---|
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sano Informed Prescribing, Inc. is creating game-changing personal and population health management capabilities, previously unattainable in the healthcare market, by revolutionizing medication therapy through the fast, clinically precise detection of medications in patients. The vision of Sano Informed Prescribing is to improve individual and population health; enable healthcare professionals to evaluate, adjust and implement best possible medication therapy programs; and reduce the costs associated with quality healthcare. Sano Informed Prescribing’s mission is to ensure that every patient receives the most effective drug therapy possible. We will do this by providing precise, patient-specific medication analyses that empower healthcare professionals to tailor care; achieve optimal patient health outcomes and satisfaction; and impact overall healthcare costs.
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.
Impax Laboratories is a technology-based specialty pharmaceutical company utilizing our core competency in drug delivery and formulation expertise. We have a balanced business model consisting of a successful generic business targeting high-value solid oral and alternative dosage form Abbreviated New Drug Applications (ANDA), and a branded business currently focused on internally developing Central Nervous System (CNS) products where we can deliver meaningful patient benefits and develop strong intellectual property positions.